Although anti‐CD19 CAR‐T cell therapy is effective for R/R DLBCL,12, 13, 14 about 50%‐60% patients relapse after CAR‐T treatment with as high as 27% are antigen loss‐associated.15 The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.